From: Downregulation of B3GNT6 is a predictor of poor outcomes in patients with colorectal cancer
Variables | Testing cohort (n=443) | Validating cohort (n=123) | ||||
---|---|---|---|---|---|---|
High (n=170) | Low (n=273) | p value | High (n=49) | Low (n=74) | p value | |
Age | ||||||
 ≥65 | 101 | 166 | 0.7351 | 35 | 52 | 0.8901 |
 <65 | 69 | 106 |  | 14 | 22 |  |
 Unavailable | 0 | 1 |  | 0 | 0 |  |
Gender | ||||||
 Male | 90 | 147 | 0.8527 | 32 | 41 | 0.2738 |
 Female | 80 | 126 |  | 17 | 33 |  |
Stage | ||||||
 I-II | 84 | 137 | 0.9321 | 28 | 48 | 0.3882 |
 III-IV | 82 | 136 |  | 21 | 26 |  |
T stage | ||||||
 T1-T2 | 21 | 26 | 0.3574 | 2 | 11 | 0.0625 |
 T3-T4 | 145 | 239 |  | 43 | 59 |  |
 Unavailable | 4 | 8 |  | 4 | 4 |  |
Lymph node metastasis | ||||||
 Absent | 88 | 142 | 0.8803 | 26 | 46 | 0.3906 |
 Present | 76 | 119 |  | 19 | 24 |  |
 Unavailable | 6 | 12 |  | 4 | 4 |  |
Distant metastasis | ||||||
 Absent | 150 | 226 | 0.1474 | 40 | 66 | 0.3078 |
 Present | 16 | 38 |  | 4 | 3 |  |
 Unavailable | 4 | 9 |  | 5 | 5 |  |
Tumor Location | ||||||
 Distal | 96 | 171 | 0.1971 | 27 | 48 | 0.2772 |
 Proximal | 74 | 102 |  | 22 | 26 |  |
MMR | ||||||
 dMMR | 18 | 43 | 0.1222 | 5 | 9 | 0.6202 |
 pMMR | 139 | 209 |  | 41 | 55 |  |
 Unavailable | 13 | 21 |  | 3 | 10 |  |
CIMP status | ||||||
 − | 111 | 195 | 0.1855 | 38 | 61 | 0.4994 |
 + | 33 | 41 |  | 8 | 9 |  |
 Unavailable | 26 | 37 |  | 3 | 4 |  |
CIN status | ||||||
 negative | 41 | 41 | 0.0205 | 17 | 11 | 0.0059 |
 positive | 98 | 176 |  | 25 | 55 |  |
 Unavailable | 31 | 56 |  | 7 | 8 |  |
tp53 mutation | ||||||
 Mutated | 51 | 84 | 0.9483 | 20 | 35 | 0.2642 |
 Wild type | 42 | 68 |  | 24 | 27 |  |
 Unavailable | 77 | 121 |  | 5 | 12 |  |
Kras mutation | ||||||
 Mutated | 84 | 88 | 0.0002 | 20 | 25 | 0.496 |
 Wild type | 78 | 174 |  | 29 | 47 |  |
 Unavailable | 8 | 11 |  | 0 | 2 |  |
Braf mutation | ||||||
 Mutated | 19 | 25 | 0.4532 | 4 | 3 | 0.3401 |
 Wild type | 130 | 218 |  | 44 | 69 |  |
 Unavailable | 21 | 30 |  | 1 | 2 |  |